SCHEMBL2511481

SCHEMBL2511481

O=C(/C=C/c1cccc2ccn(S(=O)(=O)c3ccccc3)c12)NO

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 17/20 0.68
HDAC6 Q9UBN7 17/20 0.68
HDAC1 Q13547 17/20 0.68
HDAC3 O15379 16/20 0.68
HDAC2 Q92769 16/20 0.68
HDAC10 Q969S8 16/20 0.68
HDAC4 P56524 14/20 0.68
HDAC7 Q8WUI4 14/20 0.68
HDAC11 Q96DB2 14/20 0.68
HDAC9 Q9UKV0 14/20 0.68
HDAC5 Q9UQL6 14/20 0.68
PTGER3 P43115 1/20 0.46
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
HTR6 P50406 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2510571 1.00 HDAC8 (0.68) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL18649967 0.87 HDAC1 (0.63) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL2515782 0.87 HDAC1 (0.63) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL2515786 0.87 HDAC1 (0.63) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL8354469 0.82 HDAC3 (0.47) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL18649848 0.81 HDAC6 (1.00) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL2511705 0.81 HDAC6 (1.00) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL2511706 0.81 HDAC6 (1.00) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL2137394 0.79 L3MBTL1 (0.46) HDAC8HDAC6HDAC1HDAC3HDAC2
SCHEMBL2137392 0.79 L3MBTL1 (0.46) HDAC8HDAC6HDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552887-B1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS UNIV TAIPEI MEDICAL (TW) 2018-10-24 EP claimed
EP-2552887-B1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS UNIV TAIPEI MEDICAL (TW) 2018-10-24 EP disclosed
US-9598364-B2 Indolyl or indolinyl hydroxamate compounds TAIPEI MEDICAL UNIVERSITY (TW) 2017-03-21 US disclosed
US-9598364-B2 Indolyl or indolinyl hydroxamate compounds TAIPEI MEDICAL UNIVERSITY (TW) 2017-03-21 US disclosed
US-20140364477-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2014-12-11 US disclosed
US-20140364477-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2014-12-11 US disclosed
US-8846748-B2 Indolyl or indolinyl hydroxamate compounds TAIPEI MEDICAL UNIVERSITY (TW) 2014-09-30 US disclosed
US-8846748-B2 Indolyl or indolinyl hydroxamate compounds TAIPEI MEDICAL UNIVERSITY (TW) 2014-09-30 US disclosed
EP-2552887-A2 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS Taipei Medical University (TW) 2013-02-06 EP disclosed
WO-2011126821-A2 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2011-10-13 WO disclosed
US-20110245315-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245315-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS IDH3A, IDH2, IDH3B HDAC8 128/4885HDAC6 35/4885HDAC1 8/4885
US-20140364477-A1 INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS IDH3A, IDH2, IDH3B HDAC8 128/4885HDAC6 35/4885HDAC1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.